Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Real-world Outcomes of Tyrosine Kinase Inhibitors Immediately After Immune Checkpoint Inhibitors in Renal Cell Carcinoma

TAIGO KATO, AKIRA NAGAHARA, NORIHIKO KAWAMURA, WATARU NAKATA, TETSUJI SODA, KYOSUKE MATSUZAKI, KOJI HATANO, ATSUNARI KAWASHIMA, TAKESHI UJIKE, RYOICHI IMAMURA, KENSAKU NISHIMURA, SHINGO TAKADA, MASAO TSUJIHATA, SEIJI YAMAGUCHI, TETSUYA TAKAO, YASUTOMO NAKAI, MASASHI NAKAYAMA, NORIO NONOMURA and MOTOHIDE UEMURA
Anticancer Research November 2021, 41 (11) 5811-5816; DOI: https://doi.org/10.21873/anticanres.15398
TAIGO KATO
1Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: kato@uro.med.osaka-u.ac.jp
AKIRA NAGAHARA
2Department of Urology, Osaka International Cancer Institute, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NORIHIKO KAWAMURA
3Department of Urology, Osaka General Medical Center, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
WATARU NAKATA
4Department of Urology, Osaka Rosai Hospital, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TETSUJI SODA
5Department of Urology, Osaka Police Hospital, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KYOSUKE MATSUZAKI
6Department of Urology, National Hospital Organization Osaka National Hospital, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KOJI HATANO
1Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ATSUNARI KAWASHIMA
1Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKESHI UJIKE
1Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RYOICHI IMAMURA
1Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KENSAKU NISHIMURA
6Department of Urology, National Hospital Organization Osaka National Hospital, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHINGO TAKADA
5Department of Urology, Osaka Police Hospital, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASAO TSUJIHATA
4Department of Urology, Osaka Rosai Hospital, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SEIJI YAMAGUCHI
3Department of Urology, Osaka General Medical Center, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TETSUYA TAKAO
3Department of Urology, Osaka General Medical Center, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YASUTOMO NAKAI
2Department of Urology, Osaka International Cancer Institute, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASASHI NAKAYAMA
2Department of Urology, Osaka International Cancer Institute, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NORIO NONOMURA
1Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MOTOHIDE UEMURA
1Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Immune checkpoint inhibitors (ICIs) have demonstrated a survival benefit for patients with cancer. However, the clinical outcomes of subsequent tyrosine kinase inhibitors (TKIs) after ICI failure in patients with metastatic renal cell carcinoma (mRCC) remain unclear. Patients and Methods: We retrospectively examined 38 patients with mRCC who started TKIs immediately after nivolumab with (combination group) or without ipilimumab (nivolumab group) between September 2016 and July 2019. Results: Of the 38 patients, 16 and 11 achieved partial response and stable disease, respectively, resulting in a 42.1% objective response rate and 71.1% disease control rate. The median progression-free survival (PFS) from TKI initiation was 8.8 and 12.9 months in the nivolumab and combination groups, respectively. PFS and overall survival were significantly longer in patients with long-term responses to previous ICI treatment (p=0.0152 and p=0.0155, respectively). Conclusion: TKIs demonstrate adequate anti-tumour activity after treatment with ICIs in real-world settings.

Key Words:
  • Renal cell carcinoma
  • tyrosine kinase inhibitor
  • immune checkpoint inhibitor
  • nivolumab
  • ipilimumab
  • Received August 29, 2021.
  • Revision received September 26, 2021.
  • Accepted September 27, 2021.
  • Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
View Full Text

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles
PreviousNext
Back to top

In this issue

Anticancer Research: 41 (11)
Anticancer Research
Vol. 41, Issue 11
November 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Real-world Outcomes of Tyrosine Kinase Inhibitors Immediately After Immune Checkpoint Inhibitors in Renal Cell Carcinoma
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 5 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Real-world Outcomes of Tyrosine Kinase Inhibitors Immediately After Immune Checkpoint Inhibitors in Renal Cell Carcinoma
TAIGO KATO, AKIRA NAGAHARA, NORIHIKO KAWAMURA, WATARU NAKATA, TETSUJI SODA, KYOSUKE MATSUZAKI, KOJI HATANO, ATSUNARI KAWASHIMA, TAKESHI UJIKE, RYOICHI IMAMURA, KENSAKU NISHIMURA, SHINGO TAKADA, MASAO TSUJIHATA, SEIJI YAMAGUCHI, TETSUYA TAKAO, YASUTOMO NAKAI, MASASHI NAKAYAMA, NORIO NONOMURA, MOTOHIDE UEMURA
Anticancer Research Nov 2021, 41 (11) 5811-5816; DOI: 10.21873/anticanres.15398

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Real-world Outcomes of Tyrosine Kinase Inhibitors Immediately After Immune Checkpoint Inhibitors in Renal Cell Carcinoma
TAIGO KATO, AKIRA NAGAHARA, NORIHIKO KAWAMURA, WATARU NAKATA, TETSUJI SODA, KYOSUKE MATSUZAKI, KOJI HATANO, ATSUNARI KAWASHIMA, TAKESHI UJIKE, RYOICHI IMAMURA, KENSAKU NISHIMURA, SHINGO TAKADA, MASAO TSUJIHATA, SEIJI YAMAGUCHI, TETSUYA TAKAO, YASUTOMO NAKAI, MASASHI NAKAYAMA, NORIO NONOMURA, MOTOHIDE UEMURA
Anticancer Research Nov 2021, 41 (11) 5811-5816; DOI: 10.21873/anticanres.15398
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Primary Synovial Sarcoma of the Bone: A Case Report and Literature Review
  • Melanoma of the Lower Limbs and Hips: A Surveillance, Epidemiology, and End Results Analysis of Epidemiology and Survival 2000-2019
  • Ganglioside GD2 Expression Is Associated With Unfavorable Prognosis in Early Triple-negative Breast Cancer
Show more Clinical Studies

Similar Articles

Keywords

  • Renal cell carcinoma
  • tyrosine kinase inhibitor
  • immune checkpoint inhibitor
  • Nivolumab
  • ipilimumab
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire